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Abstract
Following a request from the European Commission, the Panel on Nutrition, Novel Foods and Food
Allergens (NDA) was asked to deliver an opinion on the safety of astaxanthin when used as a novel
food in food supplements at maximum levels of 8 mg/day, taking into account the overall cumulative
intake of astaxanthin from all food sources. In 2014, the NDA Panel assessed the safety of the novel
astaxanthin-rich ingredient derived from microalgae Haematococcus pluvialis in the context of an
application submitted under Regulation (EC) No 258/1997. In that opinion, the NDA Panel considered
that the acceptable daily intake (ADI) for astaxanthin was 0.034 mg/kg body weight (bw) set by the
EFSA FEEDAP Panel in 2014. In 2019, the FEEDAP Panel adopted an opinion which concerned the
renewal of the authorisation of dimethyldisuccinate-astaxanthin and a new use of the additive for
crustaceans and other fish than salmonids. In that assessment, the FEEDAP Panel derived a new ADI
of 0.2 mg astaxanthin/kg bw which replaced the ADI of 0.034 mg/kg bw established in 2014. By
taking into account an updated exposure assessment for astaxanthin from the background diet (fish
and crustaceans) in combination with 8 mg from food supplements, the NDA Panel concludes that (i)
such combined exposure to astaxanthin is safe for adults, (ii) 14 to < 18 years old adolescents reach
the ADI, and (iii) the ADI is exceeded by 28% in children aged 10 to < 14 years and up to 524% in
infants aged 4–6 months.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
Astaxanthin (ATX) is a pink colour extract from the alga Haematococcus pluvialis and is widely used
in the food and feed industry as a colour.
Under Commission Implementing Regulation (EU) 2017/2470 establishing the Union list of novel
foods in accordance with Regulation (EU) 2015/2283, an ATX-rich oleoresin from Haematococcus
pluvialis algae is authorised in food supplements at levels of up to 40–80 mg/day which correspond to
a maximum authorised level of 8 mg ATX per day.
The first authorisation of ATX in food supplements at the maximum levels of 8 mg/day was granted
in Sweden in 1995, before the cut-off date of 15 May 1997 when the first EU novel food regulation
((EC) No 258/1997) came into effect. Subsequently, a number of notifications of ATX pursuant to
Article 5 of Regulation (EC) No 258/1997 on novel foods were notified to the Commission based on
substantial equivalence to the Swedish authorisation from 1995.
More recently, in 2014, an application for the safety of ATX as a novel food ingredient under
Regulation (EC) No 258/1997 at maximum cumulative consumption levels of 4 mg/day coming from its
use in fermented liquid dairy products, non-fermented liquid dairy products, fermented soya products
and fruit drinks for healthy adults was evaluated by the EFSA NDA Panel.1 Using the ADI of 0.034 mg/kg
bw per day set by the FEEDAP Panel in its 2014 opinion of ATX as a feed additive,2 the NDA
Panel concluded that the intake of ATX from these uses would exceed the ADI at least two-fold.
Consequently, the Panel concluded that safety of ATX for these uses could not be established.
In light of the above, it would seem that the intake from the authorised use levels of 8 mg/day of
ATX in food supplements would exceed the ADI and thus may not be in accordance with the
conditions set out in Article 7 of Regulation (EU) 2015/2283. In addition, there seem to be other
sources of exposure to ATX which would contribute to the overall intake. On the other hand, during
the public consultation of the draft Implementing Regulation establishing the Union list,3 food business
operators who are placing ATX on the market in food supplements or in other approved food uses in
other regions (i.e. outside of the EU), claim that there is a substantial body of evidence on the safety
of ATX.
In accordance with Article 29(1) of Regulation (EC) No 178/2002, the EC tasked EFSA to evaluate
whether the safety of ATX used as a NF in food supplements at maximum levels of 8 mg/day is still in
accordance with the requirements of Regulation (EU) 2015/2283,4 taking into account the overall,
cumulative intakes of ATX from all sources, including from its approved uses in food supplements and
in other foods. In doing so, EFSA should solicit and make use of the most recent toxicological and
exposure evidence which may be available to business operators and in the public domain.
2. Data and methodologies
2.1. Data
The data considered in this assessment are (i) previous assessments of ATX by EFSA Panels in 2014
(EFSA NDA Panel, 2014; EFSA FEEDAP Panel, 2014a,b), (ii) information received by the European
Commission during the public consultation of the draft Union list (European Commission, 2017), (iii) an
updated safety assessment by the EFSA FEEDAP Panel from 2019 on synthetic ATX dimethyldisuccinate
(DMDS) (EFSA FEEDAP Panel, 2019), (iv) information received from a public call for data by EFSA,5
and (v) information retrieved by EFSA from an extensive literature search.
2.2. Methodologies
The extensive literature search on ATX consulted the following scientific databases: ‘Scopus’,
‘Pubmed’, ‘Scifinder’ and ‘Web of Science’. The search was targeted to identify scientific evidence
1 EFSA Journal 2014; 12(7):3757. https://www.efsa.europa.eu/it/efsajournal/pub/3757
2 EFSA Journal 2014; 12(6):3274. https://www.efsa.europa.eu/it/efsajournal/pub/3724
3 https://ec.europa.eu/info/law/better-regulation/initiatives/ares-2017-4851094/feedback_de?p_id=119856
4 https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32015R2283&from=EN
5 https://www.efsa.europa.eu/en/consultations/call/180725
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available in peer-reviewed scientific papers in relation to ATX and toxicological data and studies
reporting adverse health outcomes in humans.
3. Assessment
In 2014, the NDA Panel assessed the safety of the Novel Food (NF) ATX-rich ingredient derived from
microalgae Haematococcus (H.) pluvialis in the context of an application submitted under Regulation (EC)
No 258/1997 (EFSA NDA Panel, 2014). In that opinion, the Panel noted that the proposed maximum daily
intake of 4 mg ATX (0.06 mg/kg bodyweight (bw) for an adult weighing 70 kg) from the NF would
exceed the acceptable daily intake (ADI) for ATX of 0.034 mg/kg bw per day (corresponding to
approximately 2.4 mg for an adult person) established by the EFSA FEEDAP Panel (2014a).
In 2019, the FEEDAP Panel adopted an opinion on the safety and efficacy of ATX-DMDS
(dimethyldisuccinate (EFSA FEEDAP Panel, 2019), a colouring feed additive, for salmonids, crustaceans
and other fish.6 This Opinion addressed mainly the renewal of the authorisation of ATX-DMDS7 (aimed
at demonstrating that the additive remains safe for the target species, consumer, user8 and
environment) and the new use of the additive for crustaceans and other fish than salmonids. For that
assessment, the FEEDAP Panel considered previous risk assessments performed by EFSA (EFSA, 2005;
EFSA FEEDAP Panel, 2007, 2014a,b; EFSA NDA Panel, 2014) and data from a structured literature
search performed by the applicant. This literature search was not limited to synthetic ATX-DMDS but
was designed to identify also data on ATX produced by microorganisms. Furthermore, the FEEDAP
Panel was provided with data from stakeholders responding to the EFSA call for data who gave their
consent that the FEEDAP Panel can make use of this information for its reassessment.
In their reassessment of the toxicological profile of ATX, the FEEDAP Panel confirmed that ATX was
neither mutagenic nor carcinogenic and established an ADI of 0.2 mg ATX/kg bw per day by applying
an uncertainty factor of 200 to an lowest observed adverse effect level (LOAEL) of 40 mg/kg bw per
day for the increased incidence of multinucleated hepatocytes observed in a 2-year carcinogenicity
study in rats. The FEEDAP Panel repealed the ADI of 0.034 mg/kg bw established in 2014.
The FEEDAP Panel noted that no new repeated-dose toxicological studies were provided with the
application on synthetic ATX-DMDS. However, the FEEDAP Panel referred to six repeated-dose toxicity
studies which were not considered in their previous assessment from 2014 (Takahashi et al., 2004;
Stewart et al., 2008; Katsumata et al., 2014; Tago et al., 2014; Buesen et al., 2015; Lin et al., 2017).
According to the FEEDAP Panel, these studies did not affect the assessment because they were either
conducted with non-synthetic sources of ATX or their no observed adverse effect levels (NOAELs) were
higher than the one established for subchronic studies in the 2014 opinion (EFSA FEEDAP Panel,
2014a,b). Two of these studies (Takahashi et al., 2004; Stewart et al., 2008) concerned ATX from
H. pluvialis and were already considered in the safety assessment of 2014 by the NDA Panel (EFSA
NDA Panel, 2014). Two oral subchronic toxicity studies in rats (Katsumata et al., 2014; Lin et al., 2017)
concerned ATX produced by bacteria for which NOAELs were derived at the highest doses tested in
both studies, i.e. 1,000 mg/kg bw and 750 mg/kg bw, respectively. The study of Tago et al. (2014)
reported that ATX produced by Phaffia rhodozyma was not genotoxic in a bacterial reverse mutation
test and in an in vivo micronucleus test and that the NOAEL in a subacute oral toxicity study in rats
was the highest dose tested (i.e. 1,000 mg/kg bw). An oral subchronic toxicity study in rats with
synthetic ATX reported an NOAEL at the highest dose tested of 700–920 mg/kg (Buesen et al., 2015).
The NDA Panel considers that the results from these studies have no impact on its previous
conclusions regarding genotoxicity and repeated dose toxicity for ATX produced from H. pluvialis (in
the light of chronic and carcinogenicity studies with synthetic ATX).
The information submitted to EFSA by in total six stakeholders who responded to the public call for
data, included published data from the literature on human studies, mechanistic, kinetic and
toxicological studies, opinions from experts contracted by stakeholders, reviews on the regulatory
status of ATX and new unpublished experimental in vitro data. These data were considered in the
6 In accordance to Article 4(1) (authorisation of a feed additive or new use of a feed additive), under Article 13(3) (modification of
the authorisation of a feed additive) and under Article 14(1) (renewal of the authorisation) of Regulation (EC) No 1831/2003.
7 Commission Regulation (EC) No 393/2008 of 30 April 2008 concerning the authorisation of astaxanthin dimethyldisuccinate as
a feed additive. OJ L 117, 1.5.2008, p. 20.
8 ‘Users’ are defined as the persons who may be exposed to the additive while handling it, when incorporating it into
premixtures or feedingstuffs or using a feedingstuff supplemented with the additive. https://efsa.onlinelibrary.wiley.com/doi/
epdf/10.2903/j.efsa.2012.2539
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assessment by the FEEDAP Panel (2019). One stakeholder did not give consent to make these data
available to the FEEDAP Panel, but this information is now addressed in this Opinion.
The information submitted by this stakeholder concerned an expert view on the two EFSA Opinions
from 2014 (EFSA FEEDAP Panel, 2014a,b; EFSA NDA Panel, 2014), which focused on mechanistic
considerations on the observed effects in the liver of female rats in a 1-year chronic and a 2-year
carcinogenicity study considered by both EFSA Panels in 2014. According to that expert view, the
observed effects in the liver should not be considered as adverse, but rather as rat-specific adaptive
responses, i.e. resulting from chronic induction of cytochrome P450. In order to support the suggested
underlying mechanism, the stakeholder provided two in vitro studies with primary female human and
rat liver cell cultures. These studies aimed to investigate the hypothesis of rat-specific induction of
cytochrome P450 and potential quantitative differences between ATX from H. pluvialis vs. synthetic
ATX regarding induction of liver enzymes.
The FEEDAP Panel (2019) discussed chronic induction of cytochrome P450 as a possible mechanism
for the observed hepatocellular hypertrophy and noted that: ‘[. . .] in the presence of histopathological
hepatocellular changes indicative of liver toxicity, such as an increased incidence of (single) cell
necrosis and multinucleated cells, hepatocellular hypertrophy might be an initial step in the
development of hepatocellular tumours.’ The NDA Panel concurs with the view that chronic induction
of cytochrome P450 would not disprove the adversity of the observed liver effects. The NDA
Panel considers that the two provided in vitro studies, although supportive to the proposed mechanism
for hepatocellular hypertrophy in rats, do not alter the conclusions for the in vivo toxicity of synthetic
and algal ATX in rats or humans. The NDA Panel, therefore, considers that the updated ADI (i.e.
0.2 mg/kg bw) derived by the FEEDAP Panel in 2019, also applies to ATX from H. pluvialis.
In its Opinion, the FEEDAP Panel also provided an updated consumer exposure assessment for ATX
residues in fish (including consumption of salmon and trout) and crustaceans following the
methodology described in the Guidance on the safety of feed additives for consumers (Table 1) (EFSA
FEEDAP Panel, 2017).
Estimates for combined intake levels for ATX from the background diet (salmonids and crustaceans)
and from 8 mg ATX from food supplements and how such a combined exposure scenario relates to
the ADI of 0.2 mg/kg bw are provided in Table 2.
Table 1: Chronic dietary exposure of consumers to ATX based on residue data in salmonids and
crustaceans – Summary statistics across European dietary surveys (EFSA FEEDAP Panel, 2019)
Population class Number of surveys
Highest exposure estimate
(mg/kg bw per day)(a)
% of the ADI
(0.2 mg/kg bw)
Infants 6 0.053 27
Toddlers (1 to < 3 years) 10 0.146 73
Other children (3 to < 10 years) 18 0.101 51
Adolescents (10 to < 18 years) 17 0.071 36
Adults (≥ 18 years) 17 0.060 30
Elderly (≥ 65 years) 14 0.056 28
(a): Highest values of the P95 among the surveys, except for toddlers where the P90 from one survey was the highest value
(higher than the P95 of all other surveys with toddlers).
Table 2: Combined chronic dietary exposure scenario for ATX from the diet and supplements and
its relation to the ADI of 0.2 mg/kg bw
Population class
Highest exposure
estimate (mg/kg
bw per day)(a)
Default
body
weight(b)
8 mg ATX
from FS(c)
(mg/kg bw
per day)
Combined
exposure
estimate(d)
(mg/kg bw
per day)
Exceedance of the
ADI with Combined
exposure
mg/kg bw %(e)
Infants (4 to
< 6 months)
0.053 6.7 1.194 1.247 1.047 524
Infants (6 to
< 12 months)
8.8 0.909 0.962 0.762 381
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4. Discussion
When considering an exposure to ATX from the background diet together with 8 mg ATX per day
from food supplements, adults with a default body weight of 70 kg are exposed to ATX at 0.174 mg/kg
bw per day, which is about 13% below the ADI. Such a combined exposure scenario for adolescents
aged 14 to < 18 years with a default body weight of 61.3 kg results in an exposure of approximately
0.2 mg/kg bw per day which corresponds to the ADI. Adolescents aged 10 to < 14 years (with a default
body weight of 43.3 kg) exceed the ADI of 0.2 mg/kg bw per day by 0.056 mg/kg bw per day
(exceedance of the ADI by 28%) at such combined exposure scenarios. The exceedance for children
below 10 years of age ranges approximately from 0.25 to 1 mg per kg bw per day (exceeding the ADI
by 123–524%).
5. Conclusion
The Panel concludes that an intake of 8 mg ATX per day from food supplements is safe for adults
even in combination with the high exposure estimate to ATX from the background diet.
Adolescents at 14 to < 18 years of age reach the ADI in a combined exposure scenario when 8 mg
ATX from food supplements are consumed in combination with high dietary background intake
estimates.
In such a combined intake scenario of 8 mg ATX from food supplements and high exposure
estimates from the background diet, the ADI is exceeded in children below 14 years of age (from 28%
in children aged 10 to < 14 years and up to 524% in infants aged 4–6 months).
Documentation provided to the EFSA call for data
1) Response for call for data relevant to the safety assessment of ATX in the framework of
Regulation 2283/2015 – EFSA-Q-2018-00595 (valuation report of public literature on ADME,
mechanistic studies on liver effects, animal toxicity studies and human studies on ATX
together with original studies referenced therein) submitted on 12 February 2019 by Algalif
Iceland ehf.
2) Response for call for data relevant to the safety assessment of ATX in the framework of
Regulation 2283/2015 – EFSA-Q-2018-00595 (Evaluation report of data used for the previous
EFSA opinions and two new in vitro studies on ATX commissioned to HepaPredict AB);
Follow-up study to quantify the inductive liability of ATX in primary rat hepatocytes in 2D
cultures (carried out by HepaPredict AB); Study on the quantification of the inductive liability
of ATX in primary human hepatocytes in 2D cultures (carried out by HepaPredict AB))
submitted on 13 February 2018 by Intertek on behalf of AstaReal Co. Ltd.
Population class
Highest exposure
estimate (mg/kg
bw per day)(a)
Default
body
weight(b)
8 mg ATX
from FS(c)
(mg/kg bw
per day)
Combined
exposure
estimate(d)
(mg/kg bw
per day)
Exceedance of the
ADI with Combined
exposure
mg/kg bw %(e)
Toddlers (1 to
< 3 years)
0.146 11.9 0.672 0.818 0.618 309
Other children (3 to
< 10 years)
0.101 23.1 0.346 0.446 0.246 123
Adolescents
(10 to < 14 years)
0.071 43.3 0.185 0.256 0.056 28
Adolescents
(14 to < 18 years)
61.3 0.131 0.202 0.002 1
Adults (≥ 18 years) 0.060 70.0 0.114 0.174 0.026 13(e)
Elderly (≥ 65 years) 0.056 70.0 0.114 0.170 0.030 15(e)
(a): ATX exposure from consumption of fish and crustaceans.
(b): Default body weights derived from EFSA Scientific Committee (2012).
(c): Theoretical exposure to ATX FS (= food supplements) per kg bw when using default body weights from (b).
(d): Combined exposure estimate from the diet and FS.
(e): Combined exposure estimate is 13 and 15%, respectively, below the ADI.
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3) Information to the specific call for data (EFSA-Q-2018-00595) on ATX from Haematococcus
pluvialis algae (Evaluation report on previous EFSA opinions on ATX, including mechanistic
considerations and human data and a new in vitro study, original studies referenced therein);
In vitro study on the quantification of the inductive liability of ATX in 2D cultures of primary
hepatocytes from rat, mouse and human (carried out by HepaPredict AB) – Confidential final
results report and Confidential study protocol); Evaluation of the rodent findings regarding
their relevance to humans (carried out by Toxicology Knowledge Team Sweden AB (TKT))
submitted by Medfiles Ltd. on 15 February 2018 on behalf of Oriflame Cosmetics Global SA
Luxembourg.
4) Submission concerning the safety assessment of ATX (Evaluation of regulatory status and
evaluation of the isomeric differences between nATXn and sATXs, evaluation of 85 clinical
studies with ATX) submitted on 15 February 2018 by PlantaPhile Ltd.
5) AVIS de l’Agence Nationale de Securite Sanitaire de l’Alimentation, de l’Environnement et du
Travail relatif au risque de toxidermie induit par la consommation de luteine et de
zeaxanthine dans les complements alimentaires. ANSES – Saisine n° 2010-SA-0242, Maisons-
Alfort, le 25 fevrier 2011.
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ADI Acceptable Daily Intake
ATX Astaxanthin
bw Body weight
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FEEDAP EFSA Panel on Products or Substances used in Animal Feed
LOAEL Lowest Observed Adverse Effect Level
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens
NF Novel food
NOAEL No observed adverse effect level
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